Race Oncology

Established in WA: 2016
Level 2, 50 Kings Park Road, WEST PERTH, 6005
08 6377 8043
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later-stage assets, principally in the cancer field. The company's first important asset is a chemotherapy drug called Bisantrene, which was the subject of more than 40 phase II clinical studies in the 1980s and 1990s. The company was formed when unlisted Perth company Coronado Resources acquired US-based biotech company Update Pharma, which owned the technology relating to Bisantrene. As part of the acquisition process Coronado launched a successful IPO to list on the ASX as Race Oncology.
Bio last updated 06 Apr 2018

Article Timeline

Access to our data for Race Oncology is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Race Oncology is included in 1 list - Public Companies - Industrial.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

To access ,

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Total Shareholder Return as at 29/06/18

1 year TSR5 year TSR
508thRace Oncology-7%0%
722 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

$24k Bought
$0 Other
$32k Bought
Total value as at the date of the transaction
Source: Morningstar


224th↓Race Oncology$0
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer